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Abstract
Background: HPV burden is a predictor for high-grade cervical intraepithelial neoplasia and cancer. The natural
history of HPV load in young women being recently exposed to HPV is described in this paper.
Methods: A total of 636 female university students were followed for 2 years. Cervical specimens with HPV-16, -18,
-31, or -45 DNA by consensus PCR were further evaluated with type-specific and b-globin real-time PCR assays.
Proportional hazards regression was used to estimate hazard ratios (HR) of infection clearance. Generalized
estimating equations assessed whether HPV loads was predictive of HPV infection at the subsequent visit.
Results: HPV loads were consistently higher among women <25 years old, and those who had multiple sex
partners, multiple HPV type infections and smokers. HPV-16 integration was encountered only in one sample.
Infection clearance was faster among women at lower tertiles of HPV-16 (HR = 2.8, 95%CI: 1.0-8.1), HPV-18 (HR =
3.5, 95%CI: 1.1-11.2) or combined (HR = 2.4, 95%CI: 1.8-6.2) DNA loads. The relationship between HPV-16 and
HPV-18 DNA loads and infection clearance followed a clear dose-response pattern, after adjusting for age and
number of sexual partners. GEE Odds Ratios for HPV persistence of the middle and upper tertiles relative to the
lower tertile were 2.7 and 3.0 for HPV-16 and 3.8 and 39.1 for HPV-18, respectively. There was no association
between HPV-31 or -45 DNA loads and persistence.
Conclusions: The association between HPV load and persistence is not uniform across high-risk genital genotypes.
HPV-16 integration was only rarely demonstrated in young women.
Background
Sexually active women are at risk for genital infection by
human papillomavirus (HPV). Most genital HPV infec-
tions regress within two years and only a minority of
women will develop persistent HPV infection that could
eventually cause cervical intraepithelial neoplasia (CIN).
High-grade CIN (grades 2 and 3) are precursors of inva-
sive cervical cancer. Although measuring persistence has
prognostic value in understanding the natural history of
HPV infection and CIN, there is a need for studying addi-
tional virological endpoints to assist in risk prediction.
HPV-16 DNA load seems to be independently asso-
ciated with high-grade CIN and invasive cancer [1-6].
Most studies also reported that HPV load was an ancillary
marker for persistent HPV infection [3,7-11]. HPV-16 or
18 infections are cleared more slowly than infections
caused by other high-risk types [12]. Since the biological
behavior of HPV types differ, the predictive value for per-
sistence of HPV DNA load may also vary between types
[13]. We know little about type-specific viral loads and
their relation with clearance of HPV infection. Moreover,
most studies on HPV viral load have focused on older
women at risk for CIN. The evaluation of HPV viral load
in recently-infected younger women remains largely
unexplored.
Integration of high oncogenic risk HPV types (HR-HPV)
is considered to be a key event in the progression of CIN
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notion that viral integration into the host genome is a
marker of progression to CIN2/3 [15-20]. Indeed, inte-
grated HPV-16 DNA can be detected in women with
CIN-1 or normal cervical samples, although these results
were not confirmed by others [21]. It is important to
establish whether HPV integration occurs early in the
course of HPV infection to assess its contribution to carci-
nogenesis. Overall, the longitudinal assessment of HR-
HPV load and integration in the natural history of HPV
infection considering various viral outcomes such as clear-
ance and persistence has received little attention up to
now. In 1996, we began a prospective cohort study of
young women attending college in Montreal, Canada, to
investigate the epidemiologic determinants of persistent
and transient cervical HPV infections [22,23].
The focus of the current study was to assess prospec-
tively, in this cohort of young women, the time course and
association between HPV-16 integration, HPV-16, 18, 31
and 45 DNA loads, and type-specific viral outcomes.
Methods
Study subjects
Female students attending either McGill University or
Concordia University Health Clinics were invited to par-
ticipate if they intended to remain in Montreal for the
next 2 years and had not been treated for cervical dis-
ease in the last 12 months [22]. A total of 636 female
university students were recruited between November
1996 and January 1999, and were followed for 2 years;
with clinic visits every 6 months. Detailed information
was obtained at enrolment via a self-administrated ques-
tionnaire and changes in lifestyle characteristics were
obtained at each follow-up visit with an abridged ques-
tionnaire, as described previously [22]. Two cervical
samples were collected with an Accelon cervical biosam-
pler at every visit. A Papanicolaou smear was prepared
with the first sampler. The remaining cells along with
those collected with the second sampler were processed
for HPV testing. Informed consent was obtained from
all study participants. The study was reviewed and
approved by the Ethics committees from each participat-
ing institution.
HPV DNA testing
HPV DNA testing has been described elsewhere [22].
Briefly, five μl of sample DNA purified with QIAamp col-
umns (Qiagen, CA) were first amplified for b-globin with
PC04/GH20 primers to demonstrate the integrity of
extracted DNA. b-globin-positive specimens were further
tested with the L1 consensus HPV primers MY09/MY11
and HMB01 using AmpliTaq gold (Roche Diagnostic
Systems, Laval, Canada) and with the Line blot assay for
the detection of 27 genital HPV genotypes [22].
HPV-16, 18, 31 and 45 viral loads
A total of 382 specimens collected from 183 partici-
pants were positive for HPV-16, -18, -31 or -45 DNA.
Nineteen women were infected concurrently with two
or more of these genotypes. Extracted DNA from these
samples was first screened for the presence of PCR inhi-
bitors by amplification of internal controls for HPV-16,
HPV-18, HPV-31 or HPV-45, and for ί-globin DNA, as
described previously [18,24]. The presence of PCR inhi-
bitors was suspected when 1000 copies of at least one
internal control generated a signal corresponding to less
than 700 copies, as previously described [25]. All sam-
ples were free of inhibitors. Two μl of processed sample
were tested in duplicate for quantification of ί-globin
DNA to estimate the cell content of samples [18,24].
HPV-16 E6 and HPV-18 E7 DNA was quantified using
a standard protocol [26]. HPV-31 L1 DNA was mea-
sured with the assay described by Weissenborn et al.
[27]. HPV-45 E6 DNA was amplified in a Light Cycler
PCR and detection system (Roche Molecular Systems)
in a 20-μl reaction mixture containing 1× DNA Master
Hybridization Probe Mix with the Fast Start Taq DNA
polymerase (Roche Molecular Biochemicals), 0.3 pmoles
of each HPV-45 primer 45 E6-F (nucleotide position
463-486; 5’-TTAAGGACAAACGAAGATTTCACA-3’)
and 45 E6-R (nucleotide position 670-647; 5’-ACACAA-
CAGGTCAACAGGATCTAA-3’), and 50 nM of fluoro-
genic 45 E6-TM probe (nucleotide position 491-514;
FAM-5’-AGCTGGACAGTACCGAGGGCAGTG-3’-
TAMRA). Cycling parameters included an activation
step at 95°C for 10 min followed by 50 cycles at 95°C
for 15 sec, 60°C for 5 sec and 65°C for 45 sec. For each
of the four genotypes analyzed, cycle thresholds
obtained for each sample were compared to those of a
titration curve obtained by serial ten-fold dilutions of
HPV-16, 18, 31 or 45 plasmids in a fixed amount of 75
ng of human genomic DNA (Roche Diagnostics) in 10
mM Tris-HCl [pH 8.2]. Each assay consistently detected
10 HPV DNA copies (data not shown). HPV viral loads
were expressed as the number of HPV DNA copies
per cell.
HPV-16 integration assays
The presence of integrated HPV-16 was investigated with
real-time PCR assays targeting E6 and E2, as previously
described [28]. Since disruption of the E2 gene often
results in HPV integration, detection of a greater quantity
of HPV-16 E6 compared to HPV-16 E2 strongly suggests
the presence of integrated HPV-16 DNA [16,17]. Two μl
of each processed sample was tested in duplicate in each
HPV-16 E6 and E2 assays. Cycle thresholds were com-
pared to those of serial ten-fold dilutions of an HPV-16
plasmid in a fixed amount of 2,000 copies of human
genomic DNA (Roche Diagnostics). We assumed that
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ratio of copy numbers for HPV-16 E6 and E2 (HPV-16
E6/E2) in a specimen was two or higher [18,28,29].
HPV-16 integration was confirmed by restriction site
PCR (RS-PCR), a sequencing technique that demon-
strates the presence of HPV-16 and human DNA
junctions in the same amplicon [30]. Briefly, 9 HPV-16-
specific primers spanning the entire HPV-16 genome
were combined separately with 6 restriction site oligo-
nucleotides designed to anneal on selected restriction
sites on the human genome, in a two-step hemi-nested
PCR performed in a 9600 Thermal Cycler. Amplicons
were migrated in a 2% agarose gel stained with ethidium
bromide. When visible bands were obtained, direct dou-
ble-stranded PCR-sequencing was done by a cycle-
sequencing method (BigDye terminator ready reaction
kit, Perkin-Elmer) using the internal primers and a
sequencing primer on 20 ng of purified amplicon.
Statistical Methods
We used Wilcoxon rank sum tests to compare type-spe-
cific viral loads among visits. The strength of the corre-
lations among log-transformed viral load measurements
at entry and follow-up visits for all four HPV types was
measured using Pearson correlation coefficient (r). Geo-
metric means of viral loads were calculated as a function
of selected characteristics reported at the index visit of
first positivity for a specific HPV type. The Kaplan-
Meier technique was used to estimate the cumulative
probability of infection clearance as a function of time
since enrolment into the study. Proportional hazards
regression was used to estimate the relative rate of
clearance of type-specific infection, stratified by tertiles
of the respective viral load distributions [31]. Logistic
generalized estimating equations (GEE) were used to
assess whether viral load measured at a given visit was a
predictor of persistent HPV infection at the subsequent
visit [32,33]. Crude and adjusted (for age and sexual
partners) odds ratios (OR) between persistent HPV at
visit (t) and viral load at visit (t-1) within specified peri-
ods of follow-up were calculated to measure the magni-
tude of the longitudinal associations.
Results
The 636 women enrolled in the McGill-Concordia
cohort contributed 2694 completed visits (mean of 4.2
visits/subject) during an average of 21.5 months of fol-
low-up. Nearly all cervical specimens (n = 2,626, 97.4%)
were suitable for HPV testing. Among those enrolled in
the cohort, 68% completed all 5 visits, contributing a
total of 13,353 woman-months of follow-up. The mean
age of participants was 23 years (median, 21 years;
range, 17-42 years). Four in five women reported that
they were Caucasian, and one in four are smokers.
Nearly half of participants had more than 4 lifetime sex-
ual partners. The prevalence (any HPV = 29%, high risk
HPV = 22%), cumulative incidence rates (cumulative
incidence of any HPV = 36% and high risk HPV = 29%
in 2 years) and mean duration of HPV infections have
been reported elsewhere [22]. High-grade and low-grade
squamous intraepithelial lesions (SIL) were found in
only 4 and 49 Pap smears, respectively, which precluded
the analysis of association between HPV loads and SIL.
Samples positive for HPV-16 (n = 220 from 104
women, mean of 2.1 samples/woman), HPV-18 (n = 80
from 43 women, mean of 1.9 samples/woman), HPV-31
(n = 75 from 36 women, mean of 2.1 samples/woman),
o rH P V - 4 5( n=3 3f r o m1 9w o m e n ,m e a no f1 . 7s a m -
ples/woman), were further tested with type-specific
quantitative real-time PCR assays. Nineteen samples
contained more than one of the studied genotype.
Descriptive statistics of log-transformed HPV loads stra-
tified by baseline and follow-up time points are pre-
sented in Figure 1. Except for the fluctuation in HPV-45
loads, which could be due to the small number of sam-
ples, we observed no significant between-visit variation
among type-specific viral loads.
To investigate the consistency of type-specific viral load
over time we calculated correlation coefficients for mea-
surements taken in all possible pairs of visits (Table 1).
HPV loads were significantlyc o r r e l a t e do n l yw h e nc o n -
sidering consecutive visits. The strength of between-visit
correlations seemed to become weaker as time pro-
gressed. Stronger correlations between consecutive visits
were found in women with HPV-16 infection. Correla-
tion coefficients of HPV loads were non-significant when
visits 12 months apart were compared, except when viral
loads for all four HPV types were combined (Table 1 and
Figure 2).
Table 2 shows geometric mean viral loads and respec-
tive 95% confidence intervals according to selected char-
acteristics determined at the first visit in which
positivity was detected for each given HPV type. HPV
DNA loads were slightly higher among women younger
than 25 years of age, with >2 lifetime sex partners, who
were regular oral contraceptive users, and with sequen-
tial HPV co-infections but not those with concurrent
co-infections. However, confidence intervals were largely
overlapping for most comparisons. HPV DNA loads did
not show a consistent pattern of variation according to
smoking categories or condom use.
Once detected, 30% of HPV-16, 44% of HPV-18, 63%
of HPV-31 and 55% of HPV-45 infections cleared within
6 months. Table 3 shows the relative rates of clearance
of HPV infection according to the HPV DNA load for
each genotype classified into tertiles. For HPV-16 and
HPV-18, infection clearance was inversely associated
with viral load but no clear pattern of association
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ponderance of HPV-16 and HPV-18 in the cohort the
overall association between combined viral loads and
clearance maintained the inverse pattern seen with the
latter types. Figure 3 shows the cumulative rates of posi-
tivity by tertile of the combined viral load distribution.
The association between HPV viral load and persis-
tence of infection was investigated for each genotype by
calculating crude and adjusted (for age and number of
sexual partners) GEE ORs (Table 4). HPV persistence
was significantly associated with intermediate and high
viral load levels at a preceding visit for HPV-16 and
HPV-18. There was no consistent effect of viral load on
persistence for HPV-31 and HPV-45 infections.
We then investigated if persistent HPV-16 infection
and/or high HPV-16 viral loads in young women could
result in integration of HPV-16 DNA into the human
genome. Forty-eight specimens were excluded from this
analysis because they contained <15 copies of HPV-16
DNA per μl of extracted DNA. HPV-16 E6 and E2 DNA
were thus quantitated on the remaining 172 HPV-16-
positive samples that had sufficiently high viral load to
permit reliable measurement of integration. The mean
HPV-16 E6 viral load on the selected samples was 57.5 ±
324.6 DNA copies per cell (95% confidence interval, 8.6-
106.4; median, 0.92, range 0.0001-4084.7 copies per cell).
The mean HPV-16 E6/E2 ratio was 0.97 ± 0.25 (95% con-
fidence interval, 0.93-1.01; median, 0.97; range, 0.5-2.48).
Of the 172 specimens analyzed, 169 had a HPV-16 E6/E2
ratio <1.5, two samples had HPV-16 a E6/E2 ratio >1.5
and <2.0 (1.54 and 1.70) and one had a ratio above 2.
Samples collected at consecutive visits from the two par-
t i c i p a n t sw i t hH P V - 1 6r a t i o so f1 . 5 4a n d1 . 7 0y i e l d e d
HPV-16 E6/E2 ratios near or below 1.0 (data not shown).
The only sample collected from a participant that gener-
ated a HPV-16 E6/E2 above 2 (ratio of 2.48) contained
0.94 copy/cell of HPV-16 E6 DNA and was obtained at
the last visit. HPV-16 was detected only at the last of five
Figure 1 HPV loads (HPV DNA copies per cell) at enrolment and at follow-up visits (total 5 visits) among HPV-positive women for the
4 genotypes studied (Y-axis in log scale). The length of each box corresponds to the interquartile range, with the top boundary of the box
representing 75th and bottom boundary the 25th percentile. The horizontal line in the box indicates the median value. Outlier values are shown
in circles outside the boxes.
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Page 4 of 12visits attended by this participant. Normal cytology
smears were obtained at the first four visits for this parti-
cipant while a low-grade SIL smear was obtained at the
fifth visit. RS-PCR was performed on the 18 samples that
generated a HPV-16 E6/E2 ratio ≥1.2. Despite using sev-
eral primer combinations, we could not demonstrate the
presence of cellular and HPV junctions in any of the
samples tested. A minimal amount of 35 μg of cellular
DNA per test was analyzed for the only sample with a
ratio >2, unsuccessfully, which could have limited our
ability to sequence HPV-human DNA junctions.
Since we detected HPV-16 integrated forms only once,
we investigated if quantity of cellular DNA introduced
in the quantitative assays hampered our ability to mea-
sure HPV-16 E6 and E2, as reported by another group
[34]. When mixtures of episomal HPV-16 and DNA
extracted from SiHa cells were tested, we observed
interference with quantitation of HPV-16 E2 and E6
with DNA extracted from 10
6 and from 10
4 SiHa cells,
respectively (data not shown). One thousand copies of
episomal HPV-16 DNA was detected without loss of sig-
nal when tested in a mixture of DNA extracted from up
to 200,000 cells in the HPV-16 E2 assay and up to
40,000 cells in the HPV-16 E6 test (Table 5). Interfer-
ence of HPV-16 quantitation by input DNA was not an
issue in our study since all samples tested contained
≤39,200 copies of cellular DNA per test.
Discussion
We measured HPV DNA load for four high-risk types
(16, 18, 31, 45) with real-time PCR on a set of samples
collected prospectively in young women. These four gen-
otypes are amongst the most frequently detected in cervi-
cal cancer. Contrary to cross-sectional studies of older
women, the four HPV genotypes were detected at similar
loads and were not substantially different between
women with single and multiple type infections [1,11,35].
The quantitative real-time PCR assays we utilized to
estimate HPV loads were specific and reproducible
[25,28]. The number of HPV DNA copies was normal-
ized for cell content by quantitation of b-globin DNA.
The HPV-16 integration assay was devised considering
the genetic diversity of HPV-16 [28,36]. Using type-spe-
cific quantitative assays allowed isolating the effect of
HPV type loads in multiple type infections. The cohort
design also allowed testing longitudinal correlations
Table 1 Between-visit correlation coefficients of HPV type-specific and combined viral load measurements at entry
and follow-up visits in the McGill-Concordia cohort
Correlation coefficient with visit at
HPV type Visit at 6 months 12 months 18 months 24 months
16 Entry 0.5232* (30) 0.3181 (20) 0.2046 (14) 0.4583 (6)
6 months 0.7561** (27) 0.6764** (21) 0.4282 (10)
12 months 0.8295** (30) 0.5810* (17)
18 months 0.8043** (24)
18 Entry 0.0103 (10) 0.5481 (5) ND ND
6 months 0.3132 (11) 0.6612 (5) 0.2290 (4)
12 months 0.0173 (8) 0.1732 (6)
18 months 0.1655 (8)
31 Entry 0.9562** (6) 0.4242 (5) 0.5133 (5) 0.2410 (3)
6 months 0.2427 (6) 0.8063* (5) 0.5138 (5)
12 months 0.1930 (11) 0.3575 (7)
18 months 0.7289* (12)
45 Entry 0.3648 (6) ND ND ND
6 months 0.7376 (3) ND ND
12 months ND 0.9745 (3) ND
18 months ND
Above HPV types combined Entry 0.4122* (53) 0.4044* (37) 0.3769* (23) 0.6103* (12)
6 months 0.6190** (49) 0.6126** (36) 0.2280 (22)
12 months 0.5752** (49) 0.1391 (33)
18 Months 0.4116* (44)
HPV loads were measured with type-specific PCR assays and expressed as logarithmic transformation before computing correlations. Pearson correlation
coefficients are shown with number of visit pairs jointly positive for the stated type or combination in parenthesis. ND: not determined because only 2 pairs
were evaluable.
* denotes significance at 5% level of significance; ** denotes significance at 1% level of statistical significance.
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Page 5 of 12between pairs of visits. Consistent measurements for
HPV types 16, 18, and 31 were shown for the five visits
with evidence of correlation between loads among visits
within subjects, whenever statistical precision was suffi-
ciently high.
As reported by others, younger woman (<25 years) har-
bored higher HPV loads than those >25 years of age [1].
These women were possibly exposed to HPV while they
were immunologically naïve to HPV. We also observed a
somewhat greater HPV burden among current and for-
mer smokers, although not consistently for all four HPV
types. This finding could be explained by a possible
defective cell-mediated immunity against HPV induced
by tobacco [37]. Results from this cohort as well as those
of others suggest that tobacco smoking may increase the
duration of high-risk HPV infection [23,38]. This could
be explained in part by the increased replication of HPV
in women exposed to tobacco.
Although the regular use of condoms protects against
most sexually transmitted infections, they are not as
efficient against HPV infection [39]. We found a trend
with the consistent use of condoms for having higher
HPV loads for most genotypes. These results could be
biased because use of condoms may be associated with
risky sexual behavior or exposure to new sexual partners
[23]. Condom use has been associated in one study with
regression of CIN and clearance of HPV [40]. Although
oral contraceptive use did not modify the duration of
high-risk HPV infection in our cohort [23], HPV-18
DNA loads were markedly increased in women on oral
contraceptives. Oral contraceptives may also be a proxy
for a higher number of sexual partners.
HPV-16 and -18 loads were good predictors of the
duration of infection with these types but the same find-
ing was not held for HPV-31 and -45. HPV-16 load has
been reported by others to be a stronger predictor for
persistence or lesions than HPV-18, 31 or 33 loads [13].
There was a clear dose-response relationship between
HPV load and persistence of HPV-16 and HPV-18 infec-
tions. We found that clearance rates depended largely on
Figure 2 Between-visit correlation graphs of viral load measurements of four combined HPV types (HPV-16, 18, 31, 45) at enrolment
and follow-up visits (see material and methods). For example, the upper left graph shows viral load at entry versus viral load at 6 months,
the lower left graph shows viral load at entry versus viral load at 24 months.
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Page 6 of 12Table 2 Means of HPV viral loads according to selected characteristics at the first occurrence of positivity for a given
HPV type
HPV 16 HPV 18 HPV 31 HPV 45
Characteristic* N Mean 95% CI N Mean 95% CI N Mean 95% CI N Mean 95% CI
Age
<25 years 72 0.47 0.19-1.19 32 0.93 0.18-4.96 31 2.07 0.54-7.97 14 0.26 0.03-2.62
25+ years 31 0.21 0.05-1.01 11 0.08 0.03-0.46 5 0.45 0.04-5.33 5 0.09 0.01-8.02
Coinfection, other HPVs
None # 10 0.17 0.02-1.24 5 0.05 0.01-0.25 4 1.88 0.10-35.6 3 0.09 0.01-8.03
Sequential 56 0.56 0.18-1.70 21 1.61 0.14-18.18 17 1.29 0.12-14.1 8 0.06 0.00-3.37
Concurrent 38 0.25 0.06-0.93 17 0.62 0.05-7.09 15 1.76 0.29-10.9 8 0.41 0.00-18.58
Smoking
Never 60 0.34 0.11-1.04 23 0.16 0.02-1.05 22 0.66 0.09-4.49 11 0.17 0.03-8.28
Current 25 0.79 0.21-2.91 15 1.29 0.18-9.36 8 1.80 0.38-8.56 3 0.32 0.05-2.46
Former 18 0.13 0.02-1.07 5 3.86 0.04-37.47 6 21.87 2.26-211.3 5 0.17 0.03-11.18
Condom use
No 15 0.09 0.01-1.05 10 0.72 0.01-44.43 4 0.49 0.02-122. 3 0.03 0.003-2.48
Used sometimes 44 0.78 0.21-2.82 17 0.35 0.04-3.34 13 6.09 0.70-53.1 12 0.33 0.02-6.19
Regular use 39 0.51 0.17-1.48 15 0.72 0.08-6.92 16 1.01 0.15-6.68 5 0.22 0.02-16.23
Oral contraceptive use
No 23 0.28 0.04-1.80 13 0.22 0.02-2.18 10 0.51 0.04-2.09 7 0.13 0.01-1.57
Infrequent 63 0.42 0.16-1.08 25 0.69 0.13-3.65 21 0.91 0.19-4.34 10 0.46 0.02-9.44
Regular 7 1.10 0.18-67.6 4 1.92 1.3-3.82 4 7.4 2.08-26.7 2 0.98 0.01-54.21
Sexual partners
One 5 0.05 0.01-6.12 5 0.02 0.04-9.03 2 0.80 0.03-205. 5 0.06 0.01-3.60
2-3 24 0.72 0.16-3.16 7 2.30 0.04-146.1 13 3.32 0.31-34.9 2 0.06 0.005-6.57
4+ 75 0.34 0.14-0.90 31 0.59 0.13-2.62 21 1.09 0.23-5.04 12 0.41 0.03-5.61
* Defined at the time of first occurrence of positivity for the stated HPV type.
# Concurrent coinfection defined as the detection of more than one HPV type in the cervical cell specimen collected at the first visit when the stated type was
found. Sequential coinfection defined as additional HPV types detected at different visits than the one when the stated type was found.
Table 3 Relative rates* of type-specific and combined HPV infection clearance according to viral load
Relative rate (95%CI)
HPV type Viral load tertile No. of Events/No. Eligible cases Unadjusted Adjusted
16 Third 5/27 1.0 1.0
Second 8/27 1.52 (0.49-4.69) 1.31 (0.41-4.20)
First 13/27 2.55 (0.90-7.24) 2.38 (0.82-6.89)
18 Third 4/13 1.0 1.0
Second 3/13 1.64 (0.31-8.78) 1.14 (0.18-7.35)
First 11/13 4.76 (1.23-18.45) 4.61 (1.17-18.05)
31 Third 6/10 1.0 1.0
Second 3/10 0.87 (0.21-3.69) 0.80 (0.19-3.44)
First 2/9 0.67 (0.16-2.75) 0.66 (0.15-2.97)
45 Third 3/6 1.0 1.0
Second 4/6 1.99 (0.21-19.02) 1.59 (0.15-16.91)
First 3/6 2.25 (0.20-25.09) 2.06 (0.17-24.27)
Above HPV types combined Third 20/55 1.0 1.0
Second 22/55 1.45 (0.79-2.64) 1.49 (0.81-2.74)
First 24/56 2.11 (1.16-3.86) 2.21 (1.19-4.10)
* Using Cox proportional hazards regression. Rate of clearance for third viral load tertile (highest) taken as referent. For the analysis of combined types the
observations are not independent and required a robust variance estimator. Adjusted relative rates were estimated in models that included age and sexual
partners as covariates.
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Page 7 of 12Figure 3 Cumulative positivity rate for infections with HPV types 16, 18, 31, and 45 according to tertiles of cumulative viral load for
these 4 types. Unit of analysis is an individual infection episode, which makes observations not independent as a subject may contribute
multiple episodes. Dotted line: upper tertile; dashed line: middle; solid line: lower tertile viral load.
Table 4 Odds ratios for associations between persistent HPV infection at visit (t) and viral load at visit (t-1) estimated
via GEE models
OR and 95% CI
HPV type Viral load tertile No. of Events/No. Eligible cases Crude Adjusted*
16 First 29/54 1.0 1.0
Second 42/54 2.97 (1.25-7.03) 2.88 (1.22-6.87)
Third 40/54 2.47 (1.15-5.32) 2.45 (1.14-5.26)
18 First 7/21 1.0 1.0
Second 13/21 5.24 (0.65-42.52) 4.33 (0.80-23.61)
Third 17/21 10.23 (1.39-75.41) 11.33 (1.90-67.59)
31 First 14/18 1.0 1.0
Second 13/18 0.73 (0.13-4.00) 0.77 (0.15-3.80)
Third 8/18 0.22 (0.04-1.28) 0.24 (0.05-1.28)
45 First 5/9 1.0 1.0
Second 4/10 0.66 (0.05-7.99) 0.46 (0.04-5.02)
Third 5/8 1.97 (0.12-32.16) 0.92 (0.06-14.02)
Events are considered as HPV infections with the stated type at visits at times t = 2, 3, 4, and 5 as a function of viral load determined at the preceding visit.
*Adjusted for age and number of lifetime sexual partners.
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Page 8 of 12the level of HPV load. Viral-host interactions play an
influential role in the clearance of viral infections [41].
HPV has developed several mechanisms to evade the
host immune system [42]. Functional differences between
HPV-encoded proteins could also explain why some
types and variants have a better viral fitness with a
greater ability to persist [14,41,43]. For HPVs 16 and 18,
viral loads were greater with HPV co-infections at differ-
ent visits (sequential) than concurrent co-infection. In
recent studies, two or more oncogenic HPV types diag-
nosed concurrently did not confer an additional risk of
developing lesions [44,45]. All but one study confirmed
that sustained or increased viral loads, especially with
HPV-16, were predictive of persistent infection [3,5,8,11].
In a cohort of nearly 6,000 women in France, women
with HPV loads above 10 pg/ml were less likely to clear
the infection, irrespective of the age of participants [8].
Similarly, another cohort study conducted in the Nether-
lands reported that women with low HPV-16 loads were
five times more likely to clear HPV-16 infection [5]. In a
third study conducted in Brazil, there was a dose-
response relationship between increasing viral loads and
risk of incident abnormal smear over time [3].
HPV-16 integration often results in the disruption of
the E2 gene, leading to uncontrolled expression of HPV-
16 oncoproteins [14,17]. HPV-16 integration could thus
occur in the course of persistent HPV-16 infection and
increase the likelihood of progression to higher grade
lesions. Integration of the HPV-16 genome was believed
to occur at the CIN-2,3 stage and beyond [14]. Recent
studies support that integration can occur even in the
absence of CIN [15,28]. In one study conducted in
women age 15 to 19 years old [46], disruption of the E2
g e n ew a sd e m o n s t r a t e di nu pt o2 5 %o fi n c i d e n tH P V -
16 infections, suggesting that HPV-16 E2 disruption was
a common event occurring early during infection. In
contrast to this latter study, HPV-16 E2 disruption was
rare in our study population, perhaps because unlike
Collins et al [46] who studied the entire E2 gene for dis-
r u p t i o no u ra s s a yo n l yf o c u s e do nt h eh i n g er e g i o no f
E2. While disruption of E2 is thought to occur more fre-
quently in the very early phases of infection in younger
women at least one other study of older women fol-
lowed longitudinally, observed approximately 50% of
women with persistent or transient infections to have
mixed integrated and episomal forms [11]. However,
unlike our study, over 50% of these participants had Pap
smear abnormalities. Furthermore, HPV integration was
not found to be associated with persistence [11]. Results
from other cohorts are needed to assess the rate of inte-
gration and to clarify the role of HPV integration on
persistence at early stages of infection.
There are some limitations to our study. We cannot
exclude the possibility that we may have underestimated
HPV-16 integration due to HPV-16 disruption during
integration in areas outside of the E2 hinge region. Never-
theless, HPV-16 E2 hinge is the most frequently disrupted
site in studies conducted in North America [16].
The analytical sensitivity of real-time PCR assays for
quantitation of HPV-16 E6 and E2 DNA utilized in this
study has been demonstrated previously and shown to
be excellent [18,28,26]. These reagents were optimized
to avoid any influences of viral polymorphism on the
efficiency of HPV-16 DNA amplification [28]. Neverthe-
less, the clinical sensitivity and specificity of these assays
to detect HPV integration have not been thoroughly
assessed. Reconstitution experiments have demonstrated
that HPV-16 integration is detected with real time PCR
assays measuring E6 and E2 when integrated HPV-16
forms are in 100-fold excess of episomal HPV-16 DNA
[47]. Theoretically, a HPV-16 E6/E2 ratio above 1.0
could suggest integration. However, previous work on
HPV-6, HPV-16 and -33 have demonstrated that HPV
E6/E2 ratios below 2.0 results from assay variability
Table 5 Interference of background human DNA in quantitation of HPV-16 DNA with HPV-16 E6 and HPV-16 E2 real-
time PCR assays
No. of copies of human DNA Quantitation of 1000 copies of episomal HPV-16 DNA with real-time PCR assays
HPV-16 E2 HPV-16 E6
0 933 ± 13 1150 ± 39
8×1 0
3 1080 ± 35 1114 ± 7
1×1 0
4 1097 ± 38 1179 ± 148
2×1 0
4 1026 ± 149 1109 ± 59
4×1 0
4 1125 ± 15 1015 ± 46
6×1 0
4 1173 ± 10 820 ± 30
8×1 0
4 1151 ± 100 726 ± 19
1×1 0
5 1082 ± 82 787 ± 32
2×1 0
5 1071 ± 38 562 ± 20
1000 copies of HPV-16 DNA were amplified in a background of various copies of human DNA and detected in real-time PCR assays for quantitation of HPV-16 E6
and HPV-16 E2. Results are means ± 1 standard deviation of duplicate values. Repeat experiments gave similar results.
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Page 9 of 12rather than true differences between E6 and E2 quanti-
ties [2,18,29,34]. Real time PCR tests may thus be falsely
negative for HPV-16 integration in the presence of low
quantities of integrated forms and high quantities of epi-
somal forms.
We could not confirm the presence of HPV-16 integra-
tion with a standard technique identifying the presence
of HPV-human DNA junctions in the only sample with a
HPV-16 E6/E2 ratio above 2.0. However, the quantity of
sample that could be analyzed was limited. A recent
report using a similar technique to demonstrate the pre-
sence of HPV-human junctions did not find HPV-16
integration in specimens from women with low-grade
SIL [21]. Real-time PCR assays may be helpful to detect
integrated HPV forms but further studies on greater
number of specimens comparing different techniques for
detection of integrated HPV-16 need to be conducted.
In our study, few women had abnormal smears, redu-
cing our power to test the associations between HPV load
and lesion outcomes. The time interval between visits can
influence the assessment of persistence and clearance. The
majority of women in our cohort returned within 6 months
of each visit and there was only a small proportion of
women whose time interval between visits extended
beyond one year [22]. The association between higher
viral loads and persistence would only be distorted if it
had been associated differentially with time between visits.
Given that the participants were unaware of their HPV
and viral load status, this is an unlikely scenario. It is also
unlikely that their behaviour and other risk factors will
change in this short span of time. The same associations
between HPV loads and persistence were obtained when
HPV persistence was defined more stringently by using
three consecutive HPV-positive visits for the same type.
Consecutive detection of HPV DNA is due to either
ongoing viral replication, reactivation of latent infections
or new infections [48,49]. The design of our study can-
not discriminate between these three possibilities. Parti-
cipants considered as having persistent infection could
have indeed, been reinfected with another isolate of the
same HPV type. However, this seems unlikely because
women with persistent infection were all infected with
the same intratypic HPV variant. Both prevalent and
incident HPV infections were included in our analysis of
persistence, increasing the power of our analyses.
Although it may not have a direct implication on HPV
clearance, the exact duration of prevalent cases is
unknown. By including them we could have introduced
a bias because a greater proportion of prevalent HPV
infections represent persistent infections compared to
incident infections. However, our conclusions did not
change when we restricted our analyses to incident
infections (data not shown). We also analyzed the entire
cohort to utilize the clustered binary outcome of
persistence, by using the ‘visit number’ as panel variable
in logistic GEE models. Apart from the gain in precision
when using multiple visits from the same women, the
findings from these models were in agreement with
those from Cox models that analyzed clearance in indi-
vidual women by tertile of viral load. Therefore, we con-
clude that the bias incurred due to inclusion of
prevalent cases is minimal. We also doubt that misclas-
sification of HPV status may have affected our results
since there were very few women with persistent type-
specific infections who had an intervening visit with a
n e g a t i v eH P Vt e s tr e s u l ta n dm o r et h a n8 0 %o ft h e
same type persistent infections occurred during conse-
cutive visits [22].
Conclusion
In conclusion, this study demonstrates a clear associa-
tion between HPV load and persistence of HPV-16 and
18 infections in young women at the early stages of
their sexual life. The association between viral load and
infection clearance seems to be type specific and, except
for age, it is not substantially affected by sociodemo-
graphic characteristics and other risk factors for infec-
tion. More longitudinal studies are needed to clarify the
onset of HPV integration and its relationship with dis-
ease progression.
Acknowledgements
This study was supported by Canadian Institutes of Health Research
operating grants MT-13649 and MOP-53111 and team grant #83320.
Author details
1Division of Cancer Epidemiology, McGill University, Montreal, Quebec,
Canada.
2Laboratoire de Virologie Moléculaire, Centre de Recherche du
Centre Hospitalier de l’Université de Montréal, Montreal, Quebec, Canada.
3Département de Microbiologie et Immunologie, Université de Montréal,
Montreal, Quebec, Canada.
4Department of Family Medicine, McGill
University, Montreal, Quebec, Canada.
5Department of Pathology and
Obstetrics & Gynecology, the Sir Mortimer B. Davis-Jewish General Hospital
and McGill University, Montreal, Quebec, Canada.
Authors’ contributions
AVR performed the statistical analysis and drafted the first version of the
manuscript. OG performed viral load measurements and integration studies,
and interpreted their findings. HR participated in the design and
coordination of the study and collection of epidemiologic data. PT
participated in the design of the study, oversaw recruitment of subjects, and
collected samples. AF participated in the design of the study, read Pap
smears, and provided expert oversight. FC helped design the study,
supervised HPV genotyping, viral load, and integration assays, participated in
the analysis of results and helped interpreting the results and drafting of the
manuscript. EF was the study’s principal investigator, and participated in its
design and coordination, supervision of analyses, and drafting. All authors
read and approved the final manuscript and subsequent revisions.
Competing interests
Financial competing interests: None
Non-Financial competing interests: None
The authors declare that they have no competing interests
Received: 2 July 2010 Accepted: 11 November 2010
Published: 11 November 2010
Ramanakumar et al. BMC Infectious Diseases 2010, 10:326
http://www.biomedcentral.com/1471-2334/10/326
Page 10 of 12References
1. Flores R, Papenfuss M, Klimecki WT, Giuliano AR: Cross-sectional analysis of
oncogenic HPV viral load and cervical intraepithelial neoplasia. Int J
Cancer 2006, 118:1187-1193.
2. Tsai HT, Wu CH, Lai HL, Li RN, Tung YC, Chuang HY, Wu TN, Lin LJ, Ho CK,
Liu HW, Wu MT: Association between quantitative high-risk human
papillomavirus DNA load and cervical intraepithelial neoplasm risk.
Cancer Epidemiol Biomarkers Prev 2005, 14:2544-2549.
3. Schlecht NF, Trevisan A, Duarte-Franco E, Rohan T, Ferenczy A, Villa LL,
Franco EL: Viral load as a predictor of the risk of cervical intraepithelial
neoplasia. Int J Cancer 2003, 103:519-524.
4. Ylitalo N, Sorensen P, Josefsson AM, Magnusson PKE, Anderson PK,
Ponten J, Adami HO, Gyllensten UB, Melbye M: Consistent high viral load
of human papillomavirus 16 and risk of cervical carcinoma in situ: a
nested case-control study. Lancet 2000, 355:2194-2198.
5. Van Duin M, Snijders PJE, Schrijnemakers HFJ, Voorhorst FJ, Rozendaal L,
Nobbenhuis MAE, van den Brule AJC, Verheijen RHM, Helmerhorst TJ,
Meijer CJLM: Human papillomavirus 16 load in normal and abnormal
cervical scrapes: an indicator of CIN II/III and viral clearance. Int J Cancer
2002, 98:590-595.
6. Gravitt PE, Kovacic MB, Herrero R, Schiffman M, Bratti C, Hildesheim A,
Morales J, Alfaro M, Sherman ME, Wacholder S, Rodriguez AC, Burk RD:
High load for most high risk human papillomavirus genotypes is
associated with prevalent cervical cancer precursors but only HPV16
load predicts the development of incident disease. Int J Cancer 2007,
121:2787-2793.
7. Ho GYF, Burk RD, Klein S, Kadish AS, Chang CJ, PalanP BasuJ, Tachezy R,
Lewis R, Romney S: Persistant genital human papillomavirus infection as
a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995,
87:1365-1371.
8. Dalstein V, Riethmuller D, Pretet JL, Le Bail C, Sautiere JL, Carbillet JP,
Kantelip B, Schaal JP, Mougin C: Persistence and load of high-risk HPV are
predictors for development of high-grade cervical lesions: a longitudinal
French cohort study. Int J Cancer 2003, 106:396-403.
9. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD: Natural history of
cervicovaginal papillomavirus infection in young women. New Engl J Med
1998, 338:423-428.
10. Fontaine J, Hankins C, Money D, Rachlis A, Pourreaux K, Ferenczy A,
Coutlee F: Human papillomavirus type 16 (HPV-16) viral load and
persistence of HPV-16 infection in women infected or at risk for HIV. J
Clin Virol 2008, 43:307-312.
11. Kulmala SM, Shabalova IP, Petrovitchev N, Syrjanen KJ, Gyllensten UB,
Johansson BC, Syrjanen SM: Type-specific persistence of high-risk human
papillomavirus infections in the New Independent States of the former
Soviet Union Cohort Study. Cancer Epidemiol Biomarkers Prev 2007,
16:17-22.
12. Trottier H, Mahmud S, Prado J, Sobrinho JS, Costa MC, Rohan TE, Villa LL,
Franco EL: Type-specific duration of human papillomavirus infection:
implications for human papillomavirus screening and vaccination. J
Infect Dis 2008, 197:1436-1447.
13. Cuzick J: Viral load as surrogate for persistence in cervical human
papillomavirus infection. In Development in Cervical Cancer Screening and
prevention. Edited by: Franco EL, Monsonego J. Blackwell, Oxford;
1997:372-378.
14. Doorbar J: Papillomavirus life cycle organization and biomarker selection.
Dis Markers 2007, 23:297-313.
15. Kulmala SMA, Syrjanen SM, Gyllensten UB, Shabalova IP, Petrovichev N,
Tosi PT, Syrjanen KJ, Johansson BC: Early integration of high copy HPV-16
detectable in women with normal and low grade cervical cytology and
histology. J Clin Pathol 2007, 59:513-517.
16. Peitsaro P, Johansson B, Syrjanen S: Integrated human papillomavirus type
16 is frequently found in cervical cancer precursors as demonstrated by
a novel quantitative real-time PCR technique. J Clin Microbiol 2002,
40:886-891.
17. Thiery F: Transcription regulation of the papillomavirus oncogenes by
cellular and viral transcription factors in cervical carcinoma. Virology
2009, 384:375-379.
18. Fontaine J, Hankins C, Mayrand MH, Lefevre J, Money D, Gagnon S,
Rachlis A, Pourreaux K, Ferenczy A, Coutlee F: High levels of episomal and
integrated HPV-16 DNA are associated with high-grade cervical lesions
in women at risk or infected with HIV. AIDS 2005, 19:785-794.
19. Cheung JL, Lo KW, Cheung TH, Tang JW, Chan PK: Viral load, E2 gene
disruption status, and lineage of human papillomavirus type 16
infections in cervical neoplasia. J Infect Dis 2006, 194:1706-1712.
20. Briolat J, Dalstein V, Saunier M, Joseph K, Caudroy S, Pretet JL, Birembaut P,
Clavel C: HPV prevalence, viral load and physical state of HPV-16 in
cervical smears of patients with different grades of CIN. Int J Cancer
2007, 121:2198-2204.
21. Matovina M, Sabol I, Grubisic G, Gasperov NM, Grce M: Identification of
human papillomavirus type 16 integration sites in high-grade
precancerous cervical lesions. Gynecol Oncol 2009, 113:120-127.
22. Richardson H, Kelsall G, Tellier P, Voyer H, Abrahamowicz M, Coutlée F,
Franco EL: The natural history of type-specific HPV infections in female
university students. Cancer. Epidemiol Biom Prev 2003, 12:485-490.
23. Richardson H, Abrahamowicz M, Tellier PP, Kelsall G, du-Berger R,
Ferenczy A, Coutlee F, Franco EL: Modifiable risk factors associated with
clearance of type-specific cervical human papillomavirus infections in a
cohort of university students. Cancer Epidemiol Biomarkers Prev 2005,
14:1149-1156.
24. Lefevre J, Hankins C, Pourreaux K: The Canadian Women’s HIV study
Group, and F. Coutlée. Prevalence of selective inhibition of HPV-16 DNA
amplification in cervicovaginal lavages. J Med Virol 2004, 72:132-137.
25. Lefevre J, Hankins C, Pourreaux K, Voyer H: The Canadian Women’sH I V
study Group, and F. Coutlée. Real -time PCR assays using internal
Controls for quantitation of HPV-16 and b-globin DNA in cervicovaginal
lavages. J Virol Methods 2003, 144:135-144.
26. Gravitt PE, Peyton C, Wheeler C, Apple R, Higuchi R, Shah KV:
Reproducibility of HPV 16 and HPV 18 viral load quantitation using
TaqMan real-time PCR assays. J. Virol Methods 2003, 112:23-33.
27. Weissenborn SJ, Funke AM, Hellmich M, Mallmann P, Fuschs PG, Pfister HG,
Wieland : Oncogenic Human papillomavirus DNA loads in human
immunodeficiency virus-positive women with High-grade cervical
lesions are strongly elevated. J Clin Microbiol 2003, 41:2763-2767.
28. Azizi N, Brazete J, Hankins C, Money J, Fontaine A, Koushik A, Rachlis K,
Pourreaux A, Franco Ferenczy E, Coutlee F: Influence of HPV-16 E2
polymorphism on quantitation of HPV-16 episomal and integrated DNA
in cervicovaginal lavages from women with cervical intraepithelial
neoplasia. J Gen Virol 2008, 89:1716-1728.
29. Khouadri S, Villa LL, Gagnon S, Koushik A, Richardson H, Ferenczy A,
Matlashewski , Roger M, Franco EL, Coutlée F: Viral load of episomal and
integrated forms of Human papillomavirus type 33 in High-grade
squamous intraepithelial lesions of the uterine cervix. Int J Cancer 2007,
121:2674-2681.
30. Thorland EC, Myers SL, Persing DH, Sarkar G, McGovern RM, Gostout BS,
Smith DI: Human papillomavirus type 16 integrations in cervical tumors
frequently occur in common fragile sites. Cancer Res 2000, 60:5916-5921.
31. Cox DR: Regression Models and Life Tables. Journal of the Royal Statistical
Society 1972, 34:187-220, Series B.
32. Liang KY, Zeger SL: Generalized linear model in longitudinal data
analysis. Biometrika 1986, 73:13-22.
33. Hardin JW, Hilbe JM: Generalized estimating equations. New York.
Chapman and Hall/CRC; 2003.
34. Ruutu MP, Kulmala SM, Peitsaro P, Syrjanen SM: The performance of the
HPV16 real-time PCR integration assay. Clin Biochem 2008, 41:423-428.
35. Snijders PJF, Hogewoning CJ, Hesselink HT, Berkhof J, Voohorst FJ,
Bleeker MC, Meijer CJLM: Determination of viral load thresholds in
cervical scrapes to rule out CIN3 in HPV 16, 18, 31 and 33-positive
women with normal cytology. Int J Cancer 2006, 119:1102-1107.
36. Coutlee F, Mayrand MH, Roger M, Franco EL: Detection and typing of
human papillomavirus nucleic acids in biological fluids. Public Health
Genomics 2009, 12:308-318.
37. Poppe WA, Ide PS, Drijkoningen MP, Lauweryns JM, Van Assche FA:
Tobacco smoking impairs the local immunosurveillance in the uterine
cervix. An immunohistochemical study. Gynecol Obstet Invest 1995,
39:34-38.
38. Giuliano AR, Sedjo RL, Roe DJ, Harri R, Baldwi S, Papenfuss MS,
Abrahamsen M, Inserra P: Clearance of oncogenic human papillomavirus
(HPV) infection: effect of smoking (United States). Cancer Causes Control
2002, 13:839-846.
39. Burchell AN, Tellier PP, Hanley J, Coutlee F, Franco EL: HPV infection in
young adult couples in new sexual relationships: the importance of
partner’s HPV status. Sex Transm Dis 2010, 37(1):34-40.
Ramanakumar et al. BMC Infectious Diseases 2010, 10:326
http://www.biomedcentral.com/1471-2334/10/326
Page 11 of 1240. Bleeker MC, Hogewoning CJ, Voorhorst FJ, van den Brule AJ, Snijders PJ,
Starink TM, Berkhof J, Meijer CJ: Condom use promotes regression of
human papillomavirus-associated penile lesions in male sexual partners
of women with cervical intraepithelial neoplasia. Int J Cancer 2003,
107:804-810.
41. Wang SS, Hildesheim A: Viral and host factors in human papillomavirus
persistence and progression. J Natl Cancer Inst Monogr 2003, 35-40.
42. Lehoux M, D’Abramo CM, Archambault J: Molecular mechanisms of
human papillomavirus-induced carcinogenesis. Public Health Genomics
2009, 12:268-280.
43. Burk RD, Chen Z, Van Doorslaer K: Human papillomaviruses: genetic basis
of carcinogenicity. Public Health Genomics 2009, 12:281-290.
44. Levi JE, Fernandes S, Tateno AF, Motta E, Lima LP, Eluf-Neto J, Pannuti CS:
Presence of multiple human papillomavirus types in cervical samples
from HIV-infected women. Gyn Oncol 2004, 92:225-231.
45. An HJ, Cho NH, Lee SY, Kim IH, Lee C, Kim SJ, Mun M, Kim SH, Jeong JK:
Correlation of cervical carcinoma and precancerous lesions with human
papillomavirus (HPV) genotypes detected with the HPV DNA chip
microarray method. Cancer 2003, 97:1672-1680.
46. Collins SI, Williams CC, Wen K, Young LS, Roberts S, Murray PG,
Woodman CB: Disruption of the E2 gene is a common and early event
in the natural history of cervical human papillomavirus infection: a
longitudinal cohort study. Cancer Res 2009, 69:3828-3832.
47. Arias-Pulido H, Peyton CL, Joste NE, Vargas H, Wheeler CM: Human
papillomavirus type 16 integration in cervical carcinoma in situ and in
invasive cervical cancer. J Clin Microbiol 2006, 44:1755-1762.
48. Cuzick J, Beverley E, Ho L, Terry G, Sapper H, Mielzynska I, Lorincz A,
Chan WK, Krausz T, Soutter P: HPV testing in primary screening of older
women. Br J Cancer 1999, 81:554-8.
49. Cuschieri KS, Cubie HA, Whitley MW, Gilkison G, Arends MJ, Graham C,
McGoogan E: Persistent high risk HPV infection associated with
development of cervical neoplasia in a prospective population study. J
Clin Pathol 2005, 58:946-950.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2334/10/326/prepub
doi:10.1186/1471-2334-10-326
Cite this article as: Ramanakumar et al.: Human papillomavirus (HPV)
types 16, 18, 31, 45 DNA loads and HPV-16 integration in persistent
and transient infections in young women. BMC Infectious Diseases 2010
10:326.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Ramanakumar et al. BMC Infectious Diseases 2010, 10:326
http://www.biomedcentral.com/1471-2334/10/326
Page 12 of 12